PET versus SPECT for determining myocardial tissue viability using fluorine-18-fluorodeoxyglucose

Frank V. Schraml, Daniel R. Driver, Thomas Randolph, Eugene D. Silverman

Research output: Contribution to journalArticle

Abstract

The U.S. Food and Drug Administration regulates the manufacture and distribution of 18F-FDG. Acquisition and use of this radiopharmaceutical for myocardial imaging at our institution required approval by our Institutional Review Board. Our initial objective was to present a scientific validation for use of this radiopharmaceutical in adjudicating the 'viable versus scarred myocardium question,' using either a PET scanner or a gamma camera equipped with 511-keV collimators. We believe that our nuclear medicine colleagues who find themselves in a similar business/legal situation regarding the acquisition and use of 18F-FDG will find this review useful. We reviewed the literature to document the efficacy of 18F-FDG, in general, in assessing myocardial viability. We then did a literature-based comparison of PET scanner methodology versus modified gamma camera methodology for imaging 18F-FDG emissions. Imaging 18F-FDG with a modified gamma camera appears to be an effective alternative to imaging with a standard PET camera for assessing myocardial viability.

Original languageEnglish (US)
Pages (from-to)272-274
Number of pages3
JournalJournal of Nuclear Medicine Technology
Volume25
Issue number4
StatePublished - Dec 1997
Externally publishedYes

Fingerprint

Tissue Survival
Fluorodeoxyglucose F18
Single-Photon Emission-Computed Tomography
Gamma Cameras
Radiopharmaceuticals
Research Ethics Committees
Nuclear Medicine
United States Food and Drug Administration
Radionuclide Imaging
Myocardium

Keywords

  • Fluorine-18-fluorodeoxyglucose
  • Gamma camera
  • Myocardial viability
  • Positron emissions

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Schraml, F. V., Driver, D. R., Randolph, T., & Silverman, E. D. (1997). PET versus SPECT for determining myocardial tissue viability using fluorine-18-fluorodeoxyglucose. Journal of Nuclear Medicine Technology, 25(4), 272-274.

PET versus SPECT for determining myocardial tissue viability using fluorine-18-fluorodeoxyglucose. / Schraml, Frank V.; Driver, Daniel R.; Randolph, Thomas; Silverman, Eugene D.

In: Journal of Nuclear Medicine Technology, Vol. 25, No. 4, 12.1997, p. 272-274.

Research output: Contribution to journalArticle

Schraml, FV, Driver, DR, Randolph, T & Silverman, ED 1997, 'PET versus SPECT for determining myocardial tissue viability using fluorine-18-fluorodeoxyglucose', Journal of Nuclear Medicine Technology, vol. 25, no. 4, pp. 272-274.
Schraml, Frank V. ; Driver, Daniel R. ; Randolph, Thomas ; Silverman, Eugene D. / PET versus SPECT for determining myocardial tissue viability using fluorine-18-fluorodeoxyglucose. In: Journal of Nuclear Medicine Technology. 1997 ; Vol. 25, No. 4. pp. 272-274.
@article{1daf3f4a585f40f0b54a7184cf95f88a,
title = "PET versus SPECT for determining myocardial tissue viability using fluorine-18-fluorodeoxyglucose",
abstract = "The U.S. Food and Drug Administration regulates the manufacture and distribution of 18F-FDG. Acquisition and use of this radiopharmaceutical for myocardial imaging at our institution required approval by our Institutional Review Board. Our initial objective was to present a scientific validation for use of this radiopharmaceutical in adjudicating the 'viable versus scarred myocardium question,' using either a PET scanner or a gamma camera equipped with 511-keV collimators. We believe that our nuclear medicine colleagues who find themselves in a similar business/legal situation regarding the acquisition and use of 18F-FDG will find this review useful. We reviewed the literature to document the efficacy of 18F-FDG, in general, in assessing myocardial viability. We then did a literature-based comparison of PET scanner methodology versus modified gamma camera methodology for imaging 18F-FDG emissions. Imaging 18F-FDG with a modified gamma camera appears to be an effective alternative to imaging with a standard PET camera for assessing myocardial viability.",
keywords = "Fluorine-18-fluorodeoxyglucose, Gamma camera, Myocardial viability, Positron emissions",
author = "Schraml, {Frank V.} and Driver, {Daniel R.} and Thomas Randolph and Silverman, {Eugene D.}",
year = "1997",
month = "12",
language = "English (US)",
volume = "25",
pages = "272--274",
journal = "Journal of Nuclear Medicine Technology",
issn = "0091-4916",
publisher = "Society of Nuclear Medicine Inc.",
number = "4",

}

TY - JOUR

T1 - PET versus SPECT for determining myocardial tissue viability using fluorine-18-fluorodeoxyglucose

AU - Schraml, Frank V.

AU - Driver, Daniel R.

AU - Randolph, Thomas

AU - Silverman, Eugene D.

PY - 1997/12

Y1 - 1997/12

N2 - The U.S. Food and Drug Administration regulates the manufacture and distribution of 18F-FDG. Acquisition and use of this radiopharmaceutical for myocardial imaging at our institution required approval by our Institutional Review Board. Our initial objective was to present a scientific validation for use of this radiopharmaceutical in adjudicating the 'viable versus scarred myocardium question,' using either a PET scanner or a gamma camera equipped with 511-keV collimators. We believe that our nuclear medicine colleagues who find themselves in a similar business/legal situation regarding the acquisition and use of 18F-FDG will find this review useful. We reviewed the literature to document the efficacy of 18F-FDG, in general, in assessing myocardial viability. We then did a literature-based comparison of PET scanner methodology versus modified gamma camera methodology for imaging 18F-FDG emissions. Imaging 18F-FDG with a modified gamma camera appears to be an effective alternative to imaging with a standard PET camera for assessing myocardial viability.

AB - The U.S. Food and Drug Administration regulates the manufacture and distribution of 18F-FDG. Acquisition and use of this radiopharmaceutical for myocardial imaging at our institution required approval by our Institutional Review Board. Our initial objective was to present a scientific validation for use of this radiopharmaceutical in adjudicating the 'viable versus scarred myocardium question,' using either a PET scanner or a gamma camera equipped with 511-keV collimators. We believe that our nuclear medicine colleagues who find themselves in a similar business/legal situation regarding the acquisition and use of 18F-FDG will find this review useful. We reviewed the literature to document the efficacy of 18F-FDG, in general, in assessing myocardial viability. We then did a literature-based comparison of PET scanner methodology versus modified gamma camera methodology for imaging 18F-FDG emissions. Imaging 18F-FDG with a modified gamma camera appears to be an effective alternative to imaging with a standard PET camera for assessing myocardial viability.

KW - Fluorine-18-fluorodeoxyglucose

KW - Gamma camera

KW - Myocardial viability

KW - Positron emissions

UR - http://www.scopus.com/inward/record.url?scp=0031463560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031463560&partnerID=8YFLogxK

M3 - Article

C2 - 9438929

AN - SCOPUS:0031463560

VL - 25

SP - 272

EP - 274

JO - Journal of Nuclear Medicine Technology

JF - Journal of Nuclear Medicine Technology

SN - 0091-4916

IS - 4

ER -